Preliminary safety, pharmacokinetics, and pharmacodynamics of duvelisib plus rituximab or obinutuzumab in patients with previously untreated CD20+ follicular lymphoma.

Carla Casulo,Eric D. Jacobsen,Koen Van Eygen,Houston Holmes,Jan Lemmens,Kerstin Allen,Lori Steelman,Veronica Campbell,Jylle Nevejans,Joseph Pearlberg,Andre Goy

Preliminary safety, pharmacokinetics, and pharmacodynamics of duvelisib plus rituximab or obinutuzumab in patients with previously untreated CD20+ follicular lymphoma.

2016

Carla Casulo
Eric D. Jacobsen
Koen Van Eygen
Houston Holmes
Jan Lemmens
Kerstin Allen
Lori Steelman
Veronica Campbell
Jylle Nevejans
Joseph Pearlberg
Andre Goy

e19052Background: Duvelisib (IPI-145), an oral dual inhibitor of PI3K-δ and -γ, is being evaluated as an oral therapeutic for hematologic malignancies as a monotherapy or in combination with anti-C...

Keywords:

Follicular lymphoma
Obinutuzumab
Rituximab
CD20
Duvelisib
Pathology
Cancer research
Medicine
Pharmacokinetics
Oncology
in patient
Internal medicine
dual inhibitor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations